Therapeutic Lifestyle Changes

Dr. Janine Darby Celebrates the Third Anniversary of Lifestyle Changes, a Physician-led Weight Management and Corporate Wellness Practice, Expanding Services to Serve a Remote Workforce and Individuals' Post-pandemic Health Issues

Retrieved on: 
Tuesday, April 26, 2022

This milestone represents growing her physician-led weight management practice to include a comprehensive corporate wellness program.

Key Points: 
  • This milestone represents growing her physician-led weight management practice to include a comprehensive corporate wellness program.
  • It also helps individuals' experiencing various health complications, including long-haul Covid, weight gain, and other lifestyle-related difficulties.
  • "I launched Lifestyle Changes in April 2019 after overseeing my weight loss through changes to my mindset, meal planning, and movement.
  • Lifestyle Changes by Dr. Janine Darby is a virtual weight management and corporate wellness practice.

Fusion Healthcare Solutions Delivers Critical PPE Including the PHG N95 Respirator, KN95 Masks, and N-Listed Wipes that Kill Covid, to Help Manage the Spread of the Highly Contagious Omicron

Retrieved on: 
Thursday, January 13, 2022

Our top-selling products are the PHG 5160 N95 respirator, KN95 masks, single-use surgical masks, and Swovo N-listed disinfecting wipes as used in medical facilities.

Key Points: 
  • Our top-selling products are the PHG 5160 N95 respirator, KN95 masks, single-use surgical masks, and Swovo N-listed disinfecting wipes as used in medical facilities.
  • These items help keep people healthy, and businesses open as the virus mutates and collides with the flu," said Mark Rubino, Founder, Fusion PPE.
  • In addition to N95 respirators, Fusion PPE offers KN95 and single-use surgical masks, along with hand sanitizers, air purifiers, wipes, and more.
  • Fusion PPE is a division of Fusion Healthcare Solutions, an established surgical and healthcare supplier since 2009.

Lifestyle Changes by Dr. Janine Darby Proves Virtual Wellness Programs are the Solution for Maintaining Physical Health and Creating a Culture of Caring Amongst Virtual Workforces

Retrieved on: 
Tuesday, January 11, 2022

Lifestyle Changes by Dr. Darby addresses this need with corporate wellness programs that combine live, online group events with virtual employee health assessments.

Key Points: 
  • Lifestyle Changes by Dr. Darby addresses this need with corporate wellness programs that combine live, online group events with virtual employee health assessments.
  • "A patient of mine valued my medical expertise and asked to extend my services to their company.
  • Dr. Darby designs programs to meet her clients' needs and they can track their progress using the Lifestyle Changes wellness journal.
  • Lifestyle Changes by Dr. Janine Darby is a virtual weight management and corporate wellness practice.

Eating a Nic's Keto Healthy Fatty Diet Reduce Body Weight and Improve Cardiovascular Health Markers!

Retrieved on: 
Wednesday, May 5, 2021

b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Key Points: 
  • b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Eating a Nic's Keto Healthy Fatty Diet Reduce Body Weight and Improve Cardiovascular Health Markers!

Retrieved on: 
Wednesday, May 5, 2021

b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

Key Points: 
  • b'Clinical trial proves that Nic\'s Keto Diet may improve markers of cardiovascular health.\nLONDON, ON, May 4, 2021 /PRNewswire/ --TRC GEN+ is happy to confirm that Prof. Nikolaos Tzenios PH.D. may have found the golden grail of Health with the optimal diet where eating a healthy fat diet reduces body weight and improves cardiovascular health markers.\nThe high-quality clinical research organization "KGK Science" Canada investigated Nic\'s Keto Diet\'s efficacy on cardiovascular Health in an open-label clinical study.\n"KGK Science" examined healthy men and women with mildly elevated LDL cholesterol levels over a period of 140 days.\nThe study\'s findings have shown that participants had a significant 4.41% reduction in body fat percentage.\nParticipants\' body weight was significantly reduced by 8.55kg.\nAfter five months of adherence to the diet plan, participants showed a significant decrease in their total cholesterol and LDL cholesterol, an increase in the HDL cholesterol, the "good cholesterol," and a significant reduction in blood sugar levels.\nOverall, the study results suggest that Nic\'s Keto Diet may be used to improve body composition and markers of cardiovascular health.\nProfessor Nikolaos Tzenios is a Professor of Public Health, Fellow of The Royal Society for Public Health (UK), Fellow of the AMERICAN ACADEMY OF ANTI-AGING MEDICINE, ASSOCIATE ACADEMICIAN of the International Academy of Social Sciences, Member of the American Academy of Regenerative Medicine, Member of The European Academy of Allergy and Clinical Immunology, Member of the Royal Society of Biology and a Postgraduate student at Global Clinical Scholars Research Training Program, Department of Postgraduate Medical Education, Harvard Medical School.\n'

VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Retrieved on: 
Monday, February 22, 2021

The Company is stepping up development of TOTUM-070 in 2021, with the completion of a complementary clinical study and preclinical work on lipid metabolism.

Key Points: 
  • The Company is stepping up development of TOTUM-070 in 2021, with the completion of a complementary clinical study and preclinical work on lipid metabolism.
  • This study should demonstrate the clinical efficacy of our active substance against excess blood LDL-cholesterol, a major risk factor for cardiovascular disease worldwide.
  • The randomized, double-blind, placebo-controlled, multicenter, Phase II HEART clinical study is designed to evaluate the efficacy of a 5g daily dose of TOTUM-070 on blood LDL-cholesterol levels, its primary endpoint.
  • Simultaneously with the HEART study, VALBIOTIS has decided to conduct a complementary clinical study to expand knowledge of TOTUM-070 and its effects on lipid metabolism in humans.

VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels

Retrieved on: 
Monday, February 15, 2021

These authorizations make it possible to begin enrolling 120 people with untreated mild to moderate LDL-hypercholesterolemia in the study.

Key Points: 
  • These authorizations make it possible to begin enrolling 120 people with untreated mild to moderate LDL-hypercholesterolemia in the study.
  • As an advisor to the HEART study, I have high hopes for the ability of TOTUM-070 to significantly reduce bad cholesterol levels in the blood.
  • The Phase II randomized, double-blind, placebo-controlled clinical study will include 120 people with untreated moderate hypercholesterolemia between 130 and 190 mg/dL.
  • The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several secondary objectives of interest.

Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association

Retrieved on: 
Tuesday, November 12, 2019

These results are consistent with the results reported from the largest long-term Phase 3 study of bempedoic acid, Study 1 or CLEAR Harmony, which were published earlier this year in the New England Journal of Medicine.

Key Points: 
  • These results are consistent with the results reported from the largest long-term Phase 3 study of bempedoic acid, Study 1 or CLEAR Harmony, which were published earlier this year in the New England Journal of Medicine.
  • Results across the Phase 3 development programme show that bempedoic acid has the potential to be a treatment option for high-risk patients who require additional LDL-C lowering.
  • Many patients remain at high risk of a cardiovascular event and need additional treatment options to achieve LDL-C goals.
  • The primary efficacy objective was to assess the 12-week LDL-C lowering efficacy of bempedoic acid versus placebo.

Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk

Retrieved on: 
Tuesday, March 12, 2019

Comedian and television host Jay Leno has partnered with Amgen to motivate patients and caregivers to get in the driver's seat as it relates to their cholesterol management.

Key Points: 
  • Comedian and television host Jay Leno has partnered with Amgen to motivate patients and caregivers to get in the driver's seat as it relates to their cholesterol management.
  • A series of videos set in Leno's famous garage sound the alarm on the connection between high cholesterol and its link to heart attack and stroke.
  • "I have high cholesterol that thankfully I am able to control with the help of my doctor, but I've learned from some close friends about its connection to their heart attack or stroke," said Leno.
  • "We hope the initiative empowers patients at high risk to understand their LDL-C levels and talk with their doctor about additional treatment options, including therapies that can reduce the risk of heart attack and stroke."